The development of social preferences

This paper examines how social preferences develop with age. This is done using a range of mini-dictator games from which we classify 665 subjects into a variety of behavioural types. We expand on previous developmental studies of pro-sociality and parochialism by analysing individuals aged 9–67, and by employing a cross country study where participants from Spain interact with participants from different ethnic groups (Arab, East Asian, Black and White) belonging to different countries (Morocco, China, Senegal and Spain). We identify a ‘U-shaped’ relationship between age and egalitarianism that had previously gone unnoticed, and appeared linear. An inverse “U-shaped” relationship is found to be true for altruism. A gender differential is found to emerge in teenage years, with females becoming less altruistic but more egalitarian than males. In contrast to the majority of previous economic studies of the development of social preferences, we report evidence of increased altruism, and decreased egalitarianism and spite expressed towards black individuals from Senegal

A Guided Tour to (Real-Life) Social Network

Limited attention has been devoted on how (real-life) social networks are elicited and mapped, even less from the viewpoint of mechanism design. This paper surveys the few mechanisms that have been proposed by the experimental literature to this purpose. These mechanisms di er in their incentive structure, as well as in the means of reward they employ. We compare these elicitation devices on the basis of the estimated di erences in the characteristics of the induced networks, such as the number of (mutual) links, correspondence and accuracy. Our main conclusion is that the elicited network architecture is itself dependent on the nature (and the structure) of the incentives. This, in turn, should provide the social scientist with guidelines on the most appropriate device to use, depending on the research objectives

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations. We aimed to assess the safety and efficacy of erlotinib compared with standard chemo therapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC. Methods We undertook the open-label, randomised phase 3 EURTAC trial at 42 hospitals in France, Italy, and Spain. Eligible participants were adults (>18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending >= 6 months before study entry was allowed). We randomly allocated participants (1: 1) according to a computer-generated allocation schedule to receive oral erlotinib 150 mg per day or 3 week cycles of standard intravenous chemotherapy of cisplatin 75 mg/m(2) on day 1 plus docetaxel (75 mg/m(2) on day 1) or gemcitabine (1250 mg/m(2) on days 1 and 8). Carboplatin (AUC 6 with docetaxel 75 mg/m(2) or AUC 5 with gemcitabine 1000 mg/m(2)) was allowed in patients unable to have cisplatin. Patients were stratified by EGFR mutation type and Eastern Cooperative Oncology Group performance status (0 vs 1 vs 2). The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. We assessed safety in all patients who received study drug (>= 1 dose). This study is registered with ClinicalTrials.gov, number NCT00446225. Findings Between Feb 15, 2007, and Jan 4, 2011, 174 patients with EGFR mutations were enrolled. One patient received treatment before randomisation and was thus withdrawn from the study; of the remaining patients, 86 were randomly assigned to receive erlotinib and 87 to receive standard chemotherapy. The preplanned interim analysis showed that the study met its primary endpoint; enrolment was halted, and full evaluation of the results was recommended. At data cutoff (Jan 26, 2011), median PFS was 9.7 months (95% CI 8.4-12.3) in the erlotinib group, compared with 5.2 months (4.5-5.8) in the standard chemotherapy group (hazard ratio 0.37, 95% CI 0.25-0.54; p<0.0001). Main grade 3 or 4 toxicities were rash (11 [13%] of 84 patients given erlotinib vs none of 82 patients in the chemotherapy group), neutropenia (none vs 18 [22%]), anaemia (one [1%] vs three [4%]), and increased aminotransferase concentrations (two [2%] vs 0). Five (6%) patients on erlotinib had treatment-related severe adverse events compared with 16 patients (20%) on chemotherapy. One patient in the erlotinib group and two in the standard chemotherapy group died from treatment-related causes. Interpretation Our findings strengthen the rationale for routine baseline tissue-based assessment of EGFR mutations in patients with NSCLC and for treatment of mutation-positive patients with EGFR tyrosine-kinase inhibitors